Benitec Biopharma Inc. (BNTC) has a negative trailing P/E of -10.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 18.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -9.33%, forward earnings yield 5.28%. PEG 0.06 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.0 | -0.03 | 2.57 | 104.15 | - |
| 2017 | -14.8 | 0.18 | 3.93 | 144.14 | - |
| 2018 | -9.8 | -0.16 | 6.08 | 183.91 | 0.15% |
| 2019 | 13.4 | -0.11 | 2.32 | 3.40 | - |
| 2020 | -3.9 | 0.01 | 3.16 | 333.10 | - |
| 2021 | -5.3 | 0.09 | 3.65 | 1,237.66 | - |
| 2022 | -2.1 | 0.07 | 13.16 | 519.41 | - |
| 2023 | -0.3 | 0.01 | 27.85 | 75.02 | - |
| 2024 | -3.4 | 0.04 | 1.58 | 0.00 | - |
| 2025 | -11.2 | 0.18 | 4.35 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-331.56 | $346.51K | $-18.5M | -5340.1% |
| 2017 | $-63.56 | $450.31K | $-4.37M | -971% |
| 2018 | $-103.61 | $455.45K | $-8.55M | -1877.4% |
| 2019 | $28.45 | $11.32M | $2.87M | 25.3% |
| 2020 | $-69.10 | $97K | $-8.3M | -8557.7% |
| 2021 | $-27.27 | $59K | $-13.78M | -23357.6% |
| 2022 | $-19.31 | $73K | $-18.56M | -25427.4% |
| 2023 | $-14.12 | $75K | $-19.56M | -26082.7% |
| 2024 | $-2.68 | $216K | $-21.75M | -10069.9% |
| 2025 | $-1.05 | $0.00 | $-37.92M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.13 | $-1.18 – $-1.04 | $25.43M | $25.43M – $25.43M | 5 |
| 2027 | $-1.11 | $-1.19 – $-1.00 | $36.43M | $36.43M – $36.43M | 5 |
| 2028 | $-0.90 | $-1.12 – $-0.68 | $50.53M | $50.53M – $50.53M | 2 |
| 2029 | $0.70 | $0.70 – $0.70 | $131.05M | $131.05M – $131.05M | 1 |
| 2030 | $2.87 | $2.87 – $2.87 | $286.79M | $286.79M – $286.79M | 1 |
